{"id":"NCT04119843","sponsor":"Ascelia Pharma AB","briefTitle":"Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function","officialTitle":"A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-19","primaryCompletion":"2023-02-17","completion":"2023-02-17","firstPosted":"2019-10-08","resultsPosted":"2025-02-06","lastUpdate":"2025-02-06"},"enrollment":87,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Known or Suspected Focal Liver Lesions","Severe Renal Impairment"],"interventions":[{"type":"DRUG","name":"Mangoral","otherNames":["Orviglance","CMC-001","ACE-MBCA"]}],"arms":[{"label":"Mangoral","type":"EXPERIMENTAL"}],"summary":"The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.","primaryOutcome":{"measure":"Co-primary Endpoint: Lesion Border Delineation in Combined MRI Compared to Unenhanced MRI","timeFrame":"Unenhanced MRI: Baseline Period (Day -1 to Day 0); combined MRI: Baseline Period (Day -1 to Day 0) and 4 hours after mangoral administration on Day 0","effectByArm":[{"arm":"Unenhanced MRI","deltaMin":2.51,"sd":0.815},{"arm":"Combined MRI","deltaMin":3.46,"sd":0.861}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":60,"countries":["United States","Argentina","Colombia","Germany","Italy","Mexico","Poland","Russia","Sweden","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":87},"commonTop":["Nausea","Diarrhoea","Vomiting","Blood urea increased","Abdominal pain"]}}